The 12-month open-label extension of TPIP in PAH patients showed sustained and robust improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved functional class 1, and 65% reached refined low-risk status, supporting…
The 12-month open-label extension of TPIP in PAH patients showed sustained and robust improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved functional class 1, and 65% reached refined low-risk status, supporting TPIP's potential as a leading prostanoid therapy.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
